Just look at market cap.
740 Mil$..... ahahah
For a drug that faces to a 4 bil$/year market......
Let's say it's selling well. So, 1 bil$ in sales (conservative)? Gives 800 mil$/years in revenues (80% in margin for drugs is normal).
What slice of 800 is takeda paying to AFFY? For how many years?
What's takeda's risk/benefit ratio? +risk of "loosing" revenues
What's BODirectors' risk/benefith ratio? +risk in staying in a company with no future for them, if omonty's sales would plummet (you never know) after few years. For what I know, AFFY is working in nothing else new at the moment.
For BOD is far better selling the farm to takeda... grabbing a multi-years paycheck and move on, with a jolly card in their diary.
So maybe it's tomorrow... or maybe it's after 2 quarters of sales report, but it's a buyout sooner or later.